Literature DB >> 8712839

Comparative percutaneous absorption of lindane and permethrin.

T J Franz1, P A Lehman, S F Franz, J D Guin.   

Abstract

BACKGROUND AND
DESIGN: Because of the concern for potential neurotoxic effects (central nervous system excitation, convulsions) in the treatment of scabies using 1% lindane lotion, 5% permethrin cream has been suggested as an alternative scabicide. Using the finite dose technique, in vitro percutaneous absorption of 5% permethrin cream or 1% lindane lotion was measured in human and guinea pig skin following a single application. In vivo blood and brain levels of the scabicides were measured in guinea pigs following three daily applications of 5% permethrin cream or 1% lindane lotion. Permethrin and lindane levels were quantified by gas chromatography/mass spectroscopy.
RESULTS: In vitro percutaneous absorption of the two scabicides was identical in guinea pig skin; however, human skin was 20-fold more permeable to lindane than to permethrin. In vivo guinea pig blood and brain levels of lindane were fourfold greater than permethrin levels.
CONCLUSION: The risk for toxic effects, as assessed by systemic exposure during overuse conditions, is projected to be 40 to 400 times lower for 5% permethrin cream than for 1% lindane lotion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8712839

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  4 in total

Review 1.  Pharmacotherapy of ectoparasitic infections.

Authors:  T C Roos; M Alam; S Roos; H F Merk; D R Bickers
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Parasitic skin infections in the elderly: recognition and drug treatment.

Authors:  H H Tan; C L Goh
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Scabies management in the community.

Authors:  L A Murphy; C Buckley
Journal:  Ir J Med Sci       Date:  2001 Apr-Jun       Impact factor: 1.568

4.  Dermal absorption of permethrin following topical administration.

Authors:  D Tomalik-Scharte; A Lazar; J Meins; B Bastian; M Ihrig; B Wachall; A Jetter; I Tantcheva-Poór; G Mahrle; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2005-06-10       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.